Using a glioblastoma treatment resistance and disease recurrence model, we show that ID-1-mediated glioblastoma progression is accompanied by upregulation of 1-C mediated de novo purine synthesis and that the resulting metabolic phenotype underlies temozolomide resistance in glioblastoma. This evidence concerns the gene ID1 and glioblastoma.